Plain-English translation of NCT06478225 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage study testing a new cell therapy called BGT007H in patients with advanced pancreatic cancer that has come back or stopped responding to standard treatments. Researchers will give patients different doses of BGT007H cells to see which dose is safest and whether the treatment can help slow or shrink the cancer. The study will include about 12 participants and carefully monitor how their bodies respond.
Most patients with advanced pancreatic cancer eventually stop responding to standard chemotherapy, and options are limited. This medication is designed to use specially prepared cells to help the immune system fight cancer, offering hope to patients who have exhausted conventional treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive an infusion of BGT007H cells through an IV. The study starts with very low doses and gradually increases the dose in new groups of participants to find the safest level. After your infusion, you will be monitored closely for at least 4 weeks to watch for side effects. If the treatment is working and you tolerate it well, you may receive additional infusions after a 1-month break. Regular blood tests and scans will track how your cancer responds.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Sponsor
RenJi Hospital
Enrollment target
~12 participants
Started
May 2024
Primary completion
March 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiuqi Wu, Doctorate
RenJi Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.